Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Eye

Volumn 24, Issue 2, 2010, Pages 203-213

  Gupta, B ^a   Elagouz, M ^a   Sivaprasad, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Choroidal neovascularisation; Non AMD

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ANGIOID STREAK; ANTIANGIOGENIC THERAPY; ARTICLE; CATARACT; CHOROIDITIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; EYE INFLAMMATION; GLAUCOMA; HUMAN; IDIOPATHIC DISEASE; IRIDOCYCLITIS; LASER COAGULATION; MULTIPLE CYCLE TREATMENT; MYOPIA; OCULAR HISTOPLASMOSIS; OCULAR TUBERCULOSIS; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA MACULA TRANSLOCATION; RETINA MACULOPATHY; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TOXOPLASMOSIS; UVEITIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

EID: 77049115673     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.201     Document Type: Article

References (86)

1. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986 93 1169-1176.
2. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coacas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996 103 1241-1244.
3. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996 37 1929-1934.
4. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996 37 855-868.
5. Doggrell SA. Pegaptanib the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother 2005 6 1421-1423.
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431.
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T et al. Ranibizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration two-year results of the ANCHOR study. Ophthalmology 2009 116 57-65.
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 113 363-372.
9. Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 26 383-390. (Pubitemid 44197628)
10. McCarty CA, Livingston PM, Taylor HR. Prevalence of myopia in adults implications for refractive surgeons. J Refract Surg 1997 13 229-234.
11. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003 87 570-573.
12. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992 12 127-133.
13. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983 90 923-926.
14. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia natural history and laser treatment. Eur J Ophthalmol 1997 7 307-316.
15. Ohno-Matsui K, Moriyama M, Hayashi K, Mochizuki M. Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006 244 1363-1366.
16. Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol 2001 131 78-89.
17. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001 85 1041-1043.
18. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001 108 841-852.
19. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 131 541-560.
20. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia a pilot study. Br J Ophthalmol 2007 91 174-179.
21. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia 12-month results. Eye 2009 23 1275-1280.
22. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007 245 903-905.
23. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009 247 311-318.
24. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O et al. Intravitreal bevacizumab Avastin) for choroidal neovascularisation secondary to pathological myopia 6-month results. Br J Ophthalmol 2008 92 1035-1039.
25. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab Avastin) for myopic choroidal neovascularization six-month results of a prospective pilot study. Ophthalmology 2007 114 2190-2196.
26. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia 12-month results. Am J Ophthalmol 2009 147 84-93.
27. Hernandez-Rojas ML, Quiroz-Mercado H, ma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solís-Vivanco A. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007 27 707-712.
28. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia oneyear results. Am J Ophthalmol 2009 147 94-100.
29. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik Jr JM. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006 26 960-963. (Pubitemid 44547453)
30. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007 125 1487-1492. (Pubitemid 350106680)
31. Rensch F, Spandau UH, Schlichtenbrede F, von Baltz S, Libondi T, Jonas JB et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008 39 182-185.
32. Rheaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008 43 576-580.
33. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez- Lopez F, Rodriguez M et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes short-term results. Eye 2007 23 334-338.
34. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007 91 161-165. (Pubitemid 46202863)
35. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008 28 1117-1123.
36. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006 26 1093-1094.
37. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization 1-year follow-up. Eye 2009 1476-5454. Electronic).
38. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007 91 157-160.
39. Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 1993 116 414-423.
40. Browning AC, Chung AK, Ghanchi F, Harding SP, Musadiq M, Talks SJ et al. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks one-year results of a prospective case series. Ophthalmology 2005 112 1227-1231.
41. Menchini U, Virgili G, Introini U, Bandello F, Ambesi- Impiombato M, Pece A et al. Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy. Retina 2004 24 763-771. (Pubitemid 39391769)
42. Arias L, Pujol O, Rubio M, Caminal J. Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefes Arch Clin Exp Ophthalmol 2006 244 753-757.
43. Shaikh S, Ruby AJ, Williams GA. Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks. Am J Ophthalmol 2003 135 1-6.
44. Heimann H, Gelisken F, Wachtlin J, Wehner A, Völker M, Foerster MH et al. Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks. Graefes Arch Clin Exp Ophthalmol 2005 243 1115-1123. (Pubitemid 43124162)
45. Molina GI, Calvo-Gonzalez C, Reche-Frutos J, Donate- López J, García-Feijoó J, Leila M et al. Intravitreal pegabtanib sodium in choroidal neovascularization secondary to angioid streaks. Acta Ophthalmol 2008 E-pub ahead of print 17 October 2008).
46. Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks. Eye 2008 22 734-735.
47. Bhatnagar P, Freund KB, Spaide RF, Klancnik Jr JM, Cooney MJ, Ho I et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007 27 897-902.
48. Derriman L, Marshall J, Moorman C, Downes SM. The use of intravitreal bevacizumab to treat choroidal neovascular membranes CNVMs). Retina 2008 28 910-911.
49. Finger RP, Charbel IP, Ladewig M, Holz FG, Scholl HP. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 2008 92 483-487.
50. Japiassu RM, Japiassu MA, Pecego MG. Intravitreal bevacizumab in choroidal neovascularization secondary to Gronblad-Strandberg syndrome case report. Arq Bras Oftalmol 2008 71 427-429.
51. Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A. Long-term control of choroidal neovascularization secondary to angioid streaks treated with intravitreal Bevacizumab AvastinR)). Br J Ophthalmol 2008 93 155-158.
52. Rinaldi M, Dell'omo R, Romano MR, Chiosi F, Cipollone U, Costagliola C. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 2007 125 1422-1423.
53. Teixeira A, Moraes N, Farah ME, Bonomo PP. Choroidal neovascularization treated with intravitreal injection of bevacizumab Avastin) in angioid streaks. Acta Ophthalmol Scand 2006 84 835-836.
54. Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS. Intravitreal bevacizumab Avastin) treatment of choroidal neovascularization in patients with angioid streaks. Br J Ophthalmol 2008 93 47-51.
55. Brown Jr J, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996 103 1100-1105.
56. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology 1984 91 1592-1602.
57. Flaxel CJ. The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients. Br J Ophthalmol 2007 91 564-565.
58. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol 1987 105 1499-1507.
59. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol 1989 107 344-352.
60. Macular Photocoagulation Study Group. Five-year followup of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol 1996 114 677-688.
61. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005 89 147-150.
62. Parodi MB, Di CL, Lanzetta P, Polito A, Bandello F, Ravalico G. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 2004 138 263-269.
63. Hawkins BS, Bressler NM, Bressler SB, Davidorf FH, Hoskins JC, Marsh MJ et al. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic I. Ophthalmic findings from a randomized clinical trial submacular Surgery Trials SST) Group H Trial SST Report No. 9. Arch Ophthalmol 2004 122 1597-1611.
64. Antonetti DA,Wolpert EB, DeMaio L, Harhaj NS, Scaduto Jr RC. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002 80 667-677.
65. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998 341 309-315.
66. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005 46 1440-1444.
67. Hogan A, Behan U, Kilmartin DJ. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 2005 89 1109-1111.
68. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 2003 110 1315-1320.
69. Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin oneyear results of a prospective series. Retina 2008 28 71-80.
70. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007 27 1180-1186. (Pubitemid 350211522)
71. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007 143 977-983.
72. Guthoff R, Goebel W. Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis. Acta Ophthalmol 2008 E-pub ahead of print 8 July 2008).
73. Mansour AM, Mackensen F, Arevalo JF, Ziemssen F, Mahendradas P, Mehio-Sibai A et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008 146 410-416.
74. Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008 145 875-878.
75. Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P et al. Intravitreal bevacizumab for refractory choroidal neovascularization CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008 246 1685-1692.
76. Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye 2008.
77. Ho AC, Yannuzzi LA, Pisicano K, DeRosa J. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 1995 102 782-789.
78. Chan WM, Lam DS, Wong TH, Lai TY, Kwok AK, Tam BS et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization one-year results from a prospective case series. Ophthalmology 2003 110 2395-2402.
79. Fujisato K, Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H et al. Two-year results of photodynamic therapy for choroidal neovascularization in young patients. Nippon Ganka Gakkai Zasshi 2008 112 777-785.
80. Kumar A, Prakash G, Singh RP. Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization. Acta Ophthalmol Scand 2004 82 205-208.
81. Leu J, Schrage NF, Degenring RF. Choroidal neovascularisation secondary to Best's disease in a 13-yearold boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2007 245 1723-1725.
82. Montero JA, Ruiz-Moreno JM, De LV. Intravitreal bevacizumab for adult-onset vitelliform dystrophy a case report. Eur J Ophthalmol 2007 17 983-986.
83. Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab Avastin). Graefes Arch Clin Exp Ophthalmol 2007 245 1731-1733.
84. Jamerson SC, Arunagiri G, Ellis BD, Leys MJ. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri. Int Ophthalmol 2008.
85. Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology 2009 116 286-296.
86. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007 143 566-583.